AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24345453 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP at 4 cm H2O
Number of subjects: 34
Study 24345453 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP at 6 cm H2O
Number of subjects: 34
Study 24345453 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP at 8 cm H2O
Number of subjects: 34
Study 22709750 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral management intervention
Number of subjects: 0
Study 22709750 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management intervention
Number of subjects: 0
Study 22709750 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (for patients with poor baseline BP control)
Number of subjects: 0
Study 22709750 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19351830 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16-positive CIN3+
Number of subjects: 412
Study 19351830 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV18/45-positive CIN3+
Number of subjects: 412
Study 19351830 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN3 positive for other carcinogenic HPV types
Number of subjects: 412
Study 17479605 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide treatment
Number of subjects: 28
Study 17479605 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 28
Study 15727381 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolterol, SR (generic diclofenac sodium sustained release tablet)
Number of subjects: 12
Study 15727381 — intervention group
Group type: COMPARATOR
Intervention: Voltaren, SR (innovator product)
Number of subjects: 12
Study 12080409 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (Sat) test meal
Number of subjects: 21
Study 12080409 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids (Trans) test meal
Number of subjects: 21
Study 12080409 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Sat and Trans meals
Number of subjects: 21
Study 9534106 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-release verapamil 240 mg/day
Number of subjects: 2400
Study 9534106 — intervention group
Group type: EXPERIMENTAL
Intervention: trandolapril 2 mg/day
Number of subjects: 2400
Study 9534106 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 180 mg/day plus trandolapril 2 mg/day
Number of subjects: 2400
Study 9534106 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2400
Study 9534106 — intervention group
Group type: EXPERIMENTAL
Intervention: trandolapril 2 mg/day plus verapamil 180 mg/day
Number of subjects: 2400
Study 7661587 — intervention group
Group type: EXPERIMENTAL
Intervention: Best supportive care plus combination chemotherapy
Number of subjects: 0
Study 7661587 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 2693623 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin alone
Number of subjects: 40
Study 2693623 — intervention group
Group type: COMPARATOR
Intervention: Triple antibiotic combination (gentamicin, clindamycin, penicillin G)
Number of subjects: 40
Study 668934 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial insemination with donor semen (AID)
Number of subjects: 114
Study 668934 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh semen
Number of subjects: 114
Study 668934 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 25 to 30
Number of subjects: 114
Study 668934 — intervention group
Group type: EXPERIMENTAL
Intervention: History of previous pregnancy
Number of subjects: 114
Study 668934 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 31 or older
Number of subjects: 114
Study 668934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic disease
Number of subjects: 114
Study 668934 — intervention group
Group type: COMPARATOR
Intervention: Freshly thawed semen
Number of subjects: 114
Study 668934 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically correctable pelvic disease treated
Number of subjects: 114
Study 668934 — intervention group
Group type: COMPARATOR
Intervention: Vaginal device for retaining semen
Number of subjects: 114
Study 668934 — intervention group
Group type: COMPARATOR
Intervention: Patient positioning
Number of subjects: 114
Study 668934 — intervention group
Group type: COMPARATOR
Intervention: Duration of infertility
Number of subjects: 114
Study 31357965 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based social cognition training (SocialMIND)
Number of subjects: 80
Study 31357965 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational multicomponent intervention (PMI)
Number of subjects: 80
Study 31357965 — intervention group
Group type: EXPERIMENTAL
Intervention: SocialMIND
Number of subjects: 80
Study 31357965 — intervention group
Group type: COMPARATOR
Intervention: PMI
Number of subjects: 80
Study 28537195 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg kg-1)
Number of subjects: 17
Study 28537195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 25801408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (7.5 mg b.i.d.)
Number of subjects: 602
Study 25801408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 25801408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 602
Study 23828185 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (10 sessions, 30-45 minutes each)
Number of subjects: 146
Study 23828185 — intervention group
Group type: COMPARATOR
Intervention: Usual care (exercise and education)
Number of subjects: 146
Study 21441549 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil patient-controlled analgesia (PCA)
Number of subjects: 0
Study 21441549 — intervention group
Group type: COMPARATOR
Intervention: Morphine patient-controlled analgesia (PCA)
Number of subjects: 0
Study 19363377 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment for MA dependence
Number of subjects: 526
Study 19363377 — intervention group
Group type: COMPARATOR
Intervention: Major depression at follow-up
Number of subjects: 526
Study 17601318 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT (Number Needed to Treat)
Number of subjects: 0
Study 15611540 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia (lidocaine 1% with adrenaline 1:100 000)
Number of subjects: 36
Study 15611540 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anaesthesia (lidocaine 1% with adrenaline 1:100 000)
Number of subjects: 36
Study 12095667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 120, 240, and 480 mg/day
Number of subjects: 15
Study 12095667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7924721 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 95
Study 7924721 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 95
Study 2530546 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ceftriaxone 2 g daily for 4 days, followed by IM or IV ceftriaxone 1 g daily for 11 days
Number of subjects: 95
Study 2530546 — intervention group
Group type: COMPARATOR
Intervention: IV ceftriaxone 2 g every other day for 4 days, followed by oral cefixime 200 mg twice daily for 11 days
Number of subjects: 95
Study 29509051 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 0
Study 27130929 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncotype DX
Number of subjects: 313
Study 27130929 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosigna (PAM50)
Number of subjects: 313
Study 27130929 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC4
Number of subjects: 313
Study 27130929 — intervention group
Group type: EXPERIMENTAL
Intervention: MammaPrint
Number of subjects: 313
Study 27130929 — intervention group
Group type: EXPERIMENTAL
Intervention: NexCourse Breast
Number of subjects: 313
Study 27130929 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtype tests (Blueprint, MammaTyper, Prosigna)
Number of subjects: 313
Study 27130929 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall risk categorization
Number of subjects: 313
Study 27130929 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant subtyping
Number of subjects: 313
Study 25769319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ji‐Tai tablet
Number of subjects: 150
Study 25769319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ji‐Tai tablet combined with buprenorphine
Number of subjects: 150
Study 25769319 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 23810466 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel + S-1 (paclitaxel 60 mg/m2 on days 1, 8, and 15; S-1 80-120 mg/d on days 1-14)
Number of subjects: 240
Study 23810466 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel + S-1
Number of subjects: 240
Study 23810466 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel + 5-fluorouracil (paclitaxel 60 mg/m2; 5-fluorouracil 500 mg/m2 on days 1-5; leucovorin 20 mg/m2 on days 1-5)
Number of subjects: 240
Study 23810466 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel + 5-fluorouracil
Number of subjects: 240
Study 20587723 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h hyperinsulinemic hypoglycemia (2.9 ± 0.1 mmol/l)
Number of subjects: 59
Study 20587723 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (5.2 ± 0.1 mmol/l)
Number of subjects: 59
Study 18249205 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 mg PSs per kilogram of body weight with a low‐cholesterol diet (C(‐)S(+))
Number of subjects: 22
Study 18249205 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 mg PSs per kilogram of body weight with a high‐cholesterol diet (C(+)S(+))
Number of subjects: 22
Study 18249205 — intervention group
Group type: COMPARATOR
Intervention: Low‐cholesterol control (C(‐)S(‐))
Number of subjects: 22
Study 18249205 — intervention group
Group type: COMPARATOR
Intervention: High‐cholesterol control (C(+)S(‐))
Number of subjects: 22
Study 18249205 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 mg PSs per kilogram of body weight (both diets)
Number of subjects: 22
Study 16324316 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive individuals (1603 subjects)
Number of subjects: 2469
Study 16324316 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-negative individuals (866 subjects)
Number of subjects: 2469
Study 16324316 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive with chronic gastritis (CAG)
Number of subjects: 2469
Study 16324316 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive with intestinal metaplasia (IM)
Number of subjects: 2469
Study 16324316 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive with dysplasia (DYS)
Number of subjects: 2469
Study 12628943 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 14
Study 12628943 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 14
Study 10389720 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly stress incontinence
Number of subjects: 2763
Study 10389720 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly urge incontinence
Number of subjects: 2763
Study 8696060 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE‐dobutamine
Number of subjects: 30
Study 8696060 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium‐201‐dipyridamole scintigraphy (TDS)
Number of subjects: 30
Study 8696060 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 30
Study 1988575 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (chemotherapy and tamoxifen)
Number of subjects: 2673
Study 1988575 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (tamoxifen and chemotherapy)
Number of subjects: 2673
Study 1988575 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 2673
Study 7039761 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2-g dose of metronidazole
Number of subjects: 163
Study 7039761 — intervention group
Group type: COMPARATOR
Intervention: Single 1-g dose of metronidazole
Number of subjects: 163
Study 7039761 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with a single 2-g dose of metronidazole after initial failure
Number of subjects: 163
Study 31805909 — intervention group
Group type: EXPERIMENTAL
Intervention: Makasi intervention (community-based outreach intervention)
Number of subjects: 188
Study 31805909 — intervention group
Group type: COMPARATOR
Intervention: Immediate arm
Number of subjects: 188
Study 31805909 — intervention group
Group type: COMPARATOR
Intervention: Deferred arm
Number of subjects: 188
Study 29692183 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (Group A) from days 1 to 14
Number of subjects: 4
Study 29692183 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (Group B) from days 15 to 28
Number of subjects: 4
Study 26508124 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled racemic adrenaline
Number of subjects: 363
Study 26508124 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 363
Study 26508124 — intervention group
Group type: EXPERIMENTAL
Intervention: High genomic load of respiratory syncytial virus (RSV)
Number of subjects: 363
Study 24976291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 88
Study 24976291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 88
Study 24976291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 21995882 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch (5%)
Number of subjects: 26
Study 21995882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 18807184 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 Fr stent placement
Number of subjects: 40
Study 18807184 — intervention group
Group type: COMPARATOR
Intervention: 10 Fr stent placement
Number of subjects: 40
Study 17547124 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD pain incidence among adolescents
Number of subjects: 2255
Study 17547124 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD pain incidence by age
Number of subjects: 2255
Study 17547124 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluctuating pattern of TMD pain
Number of subjects: 2255
Study 17547124 — intervention group
Group type: EXPERIMENTAL
Intervention: Types of TMD pain cases
Number of subjects: 2255
Study 15622223 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection followed by surgical deactivation of migraine trigger sites
Number of subjects: 125
Study 15622223 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 125
Study 15622223 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 125
Study 12095066 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 145
Study 12095066 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% gel
Number of subjects: 145
Study 10740505 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-facing profile images
Number of subjects: 24
Study 10740505 — intervention group
Group type: COMPARATOR
Intervention: Right-facing profile images
Number of subjects: 24
Study 8568113 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole treatment (n = 8)
Number of subjects: 13
Study 8568113 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 5)
Number of subjects: 13
Study 2187310 — intervention group
Group type: COMPARATOR
Intervention: Combination regimen with 0.064% betametason dipropionate ointment (Diprosis) for 1 week before dithranol therapy (B + CSV-therapy)
Number of subjects: 14
Study 2187310 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dithranol therapy (CSV-therapy)
Number of subjects: 14
Study 6993085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acebutolol
Number of subjects: 24
Study 6993085 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propranolol
Number of subjects: 24
Study 30876438 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity arm training (three times per week, over three weeks; 60 min each session; total of nine additional sessions)
Number of subjects: 78
Study 30876438 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity arm training (same quantity, frequency and treatment time as the intervention group)
Number of subjects: 78
Study 30082749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 0
Study 30082749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26900895 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session treatment (OST)
Number of subjects: 83
Study 26900895 — intervention group
Group type: COMPARATOR
Intervention: educational support (EST)
Number of subjects: 83
Study 26900895 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session treatment (OST) and educational support (EST)
Number of subjects: 83
Study 25194168 — intervention group
Group type: EXPERIMENTAL
Intervention: Group of three students per tutor
Number of subjects: 74
Study 25194168 — intervention group
Group type: EXPERIMENTAL
Intervention: Group of five students per tutor
Number of subjects: 74
Study 25194168 — intervention group
Group type: EXPERIMENTAL
Intervention: Group of eight students per tutor
Number of subjects: 74
Study 22241639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 400 mg twice a day, n=46
Number of subjects: 91
Study 22241639 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual therapy), n=45
Number of subjects: 91
Study 20068379 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 0
Study 20068379 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 0
Study 17029274 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition Dyspnea Index (TDI)
Number of subjects: 46
Study 17029274 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Dyspnea Index (BDI)
Number of subjects: 46
Study 17029274 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI)
Number of subjects: 46
Study 15175958 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol treatment (n = 27)
Number of subjects: 41
Study 15175958 — intervention group
Group type: COMPARATOR
Intervention: Non-protocol treatment (n = 14)
Number of subjects: 41
Study 15175958 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniospinal irradiation
Number of subjects: 41
Study 15175958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin chemotherapy (cumulative dose >/= 400 mg/m2)
Number of subjects: 41
Study 11182191 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (40 mg bolus followed by 60 mg/day intravenously for 48 h)
Number of subjects: 94
Study 11182191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 11182191 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 94
Study 11182191 — intervention group
Group type: COMPARATOR
Intervention: Trimetazidine and Placebo
Number of subjects: 94
Study 9638347 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg testosterone buciclate
Number of subjects: 8
Study 9638347 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg testosterone buciclate
Number of subjects: 8
Study 8074262 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler (0.5 mg terbutaline x 2)
Number of subjects: 12
Study 8074262 — intervention group
Group type: COMPARATOR
Intervention: CFC inhaler (0.25 mg terbutaline x 4)
Number of subjects: 12
Study 8074262 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 12
Study 8074262 — intervention group
Group type: COMPARATOR
Intervention: CFC inhaler
Number of subjects: 12
Study 2478045 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedian approach
Number of subjects: 49
Study 2478045 — intervention group
Group type: COMPARATOR
Intervention: Midline approach
Number of subjects: 49
Study 974569 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-applied bandages for compression sclerotherapy
Number of subjects: 0
Study 974569 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment of compression sclerotherapy
Number of subjects: 0
Study 31027110 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous aerobic exercise (MICAE) 3 times weekly for 12 weeks
Number of subjects: 46
Study 31027110 — intervention group
Group type: COMPARATOR
Intervention: Traditional intervention without any physical exercise
Number of subjects: 46
Study 28428151 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic-light system (n = 217)
Number of subjects: 442
Study 28428151 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilean warning system (n = 225)
Number of subjects: 442
Study 26581028 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 1460
Study 26581028 — intervention group
Group type: EXPERIMENTAL
Intervention: perphenazine
Number of subjects: 1460
Study 26581028 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 1460
Study 26581028 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 1460
Study 26581028 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 1460
Study 23779062 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 240 U
Number of subjects: 219
Study 23779062 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 120 U
Number of subjects: 219
Study 23779062 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (both doses)
Number of subjects: 219
Study 22165655 — intervention group
Group type: EXPERIMENTAL
Intervention: Body armor with shorter and thinner collars
Number of subjects: 71
Study 22165655 — intervention group
Group type: EXPERIMENTAL
Intervention: Collars with overlapping segments
Number of subjects: 71
Study 22165655 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher and more rigid collars
Number of subjects: 71
Study 18849173 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (1 mg)/Metformin (500 mg)
Number of subjects: 152